Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

Fig. 4

AZD9291 inhibits GBM tumorigenesis in vivo. a Mice bearing U87 xenograft tumor were treated with AZD9291 by oral administration. Representative images of H&E staining of whole brain sections from control group and AZD9291 treatment group. b The survival analysis of mice with AZD9291 treatment by oral administration. c U87 cells were transplanted into the right striatum of nude mice to establish an intracranial GBM model. Mice were sacrificed at 4 weeks after treatment via intraperitoneal injections with vehicle, AZD9291 15 mg/kg and AZD9291 30 mg/kg, respectively. Representative images of H&E staining of coronal sections from mouse brains with orthotopic tumors. d The survival of mice with tumors derived from the vehicle or AZD9291-treated groups were measured by Kaplan-Meier survival curves. e and f The effects of AZD9291 on cell proliferation and apoptosis in vivo. Cell proliferation and apoptosis of the orthotopic tumor were assessed with anti-Ki67 and anti-cleaved caspase-3 immunostaining. Scale bar: 50 μm, **P < 0.01, ***P < 0.001

Back to article page